Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.
Esophageal squamous cell carcinoma
Hepatic function test
Neoadjuvant chemoradiotherapy
Nomogram
Renal function test
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
05
06
2023
accepted:
25
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
13
11
2023
Statut:
aheadofprint
Résumé
The parameters for survival prediction of esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (NCRT) combined with surgery are unclear. Here, we aimed to construct a nomogram for survival prediction of ESCC patients treated with NCRT combined with surgery based on pretreatment serological hepatic and renal function tests. A total of 174 patients diagnosed as ESCC were enrolled as a training cohort from July 2007 to June 2019, and approximately 50% of the cases (n = 88) were randomly selected as an internal validation cohort. Univariate and multivariate Cox survival analyses were performed to identify independent prognostic factors to establish a nomogram. Predictive accuracy of the nomogram was evaluated by Harrell's concordance index (C-index) and calibration curve. ALT, ALP, TBA, TP, AST, TBIL and CREA were identified as independent prognostic factors and incorporated into the construction of the hepatic and renal function test nomogram (HRFTNomogram). The C-index of the HRFTNomogram for overall survival (OS) was 0.764 (95% CI 0.701-0.827) in the training cohort, which was higher than that of the TNM staging system (0.507 (95% CI 0.429-0.585), P < 0.001). The 5-year OS calibration curve of the training cohort demonstrated that the predictive accuracy of the HRFTNomogram was satisfactory. Moreover, patients in the high-risk group stratified by the HRFTNomogram had poorer 5-year OS than those in the low-risk group in the training cohort (27.4% vs. 80.3%, P < 0.001). Similar results were observed in the internal validation cohort. A novel HRFTNomogram might help predict the survival of locally advanced ESCC patients treated with NCRT followed by esophagectomy.
Identifiants
pubmed: 37957531
doi: 10.1007/s13304-023-01693-3
pii: 10.1007/s13304-023-01693-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Science and Technology Special Fund of Guangdong Province of China
ID : STKJ202209069
Organisme : Guangdong Basic and Applied Basic Research Foundation Enterprise Joint Foundation
ID : 2022A1515220116
Organisme : Guangdong Basic and Applied Basic Research Foundation Enterprise Joint Foundation
ID : 2022A1515220180
Organisme : Guangdong Basic and Applied Basic Research Foundation Enterprise Joint Foundation
ID : 2022A1515220182
Organisme : Youth Research Fund Project of Cancer Hospital of Shantou University Medical College
ID : 2023A005
Organisme : Guangdong Esophageal Cancer Institute Science and Technology Program
ID : M202224
Organisme : 2020 Li Ka Shing Foundation Cross-Disciplinary Research Project Fund
ID : 2020LKSFG01B
Organisme : 2020 Li Ka Shing Foundation Cross-Disciplinary Research Project Fund
ID : 2020LKSFG01D
Organisme : Guangdong Medical Science and Technology Research Program
ID : A2023414
Informations de copyright
© 2023. Italian Society of Surgery (SIC).
Références
Smyth EC, Lagergren J, Fitzgerald RC et al (2017) Oesophageal cancer. Nat Rev Dis Primers 3:17048. https://doi.org/10.1038/nrdp.2017.48
doi: 10.1038/nrdp.2017.48
pubmed: 28748917
pmcid: 6168059
Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V (2020) Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 13:1010–1021. https://doi.org/10.1007/s12328-020-01237-x
doi: 10.1007/s12328-020-01237-x
pubmed: 32965635
Abnet CC, Arnold M, Wei WQ (2018) Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154:360–373. https://doi.org/10.1053/j.gastro.2017.08.023
doi: 10.1053/j.gastro.2017.08.023
pubmed: 28823862
Shapiro J, van Lanschot JJB, Hulshof M et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098. https://doi.org/10.1016/S1470-2045(15)00040-6
doi: 10.1016/S1470-2045(15)00040-6
pubmed: 26254683
Yang H, Liu H, Chen Y et al (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 36:2796–2803. https://doi.org/10.1200/JCO.2018.79.1483
doi: 10.1200/JCO.2018.79.1483
pubmed: 30089078
pmcid: 6145832
Hou S, Pan Z, Hao X, Hang Q, Ding Y (2021) Recent progress in the neoadjuvant treatment strategy for locally advanced esophageal cancer. Cancers (Basel). https://doi.org/10.3390/cancers13205162
doi: 10.3390/cancers13205162
pubmed: 35008360
pmcid: 8625753
Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692. https://doi.org/10.1016/S1470-2045(11)70142-5
doi: 10.1016/S1470-2045(11)70142-5
pubmed: 21684205
Jing SW, Qin JJ, Liu Q et al (2019) Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis. Future Oncol 15:2413–2422. https://doi.org/10.2217/fon-2019-0024
doi: 10.2217/fon-2019-0024
pubmed: 31269806
Yuan Y, Ma G, Hu X, Huang Q (2020) Evaluating the eight edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: a SEER study. Cancer Med 9:4648–4655. https://doi.org/10.1002/cam4.2997
doi: 10.1002/cam4.2997
pubmed: 32391623
pmcid: 7333840
Hsu PK, Chen HS, Liu CC, Wu SC (2018) Application of the eighth AJCC TNM staging system in patients with esophageal squamous cell carcinoma. Ann Thorac Surg 105:1516–1522. https://doi.org/10.1016/j.athoracsur.2017.12.032
doi: 10.1016/j.athoracsur.2017.12.032
pubmed: 29409986
D’Journo XB (2018) Clinical implication of the innovations of the 8(th) of the TNM classification for esophageal and esophago-gastric cancer. J Thorac Dis 10:S2671–S2681. https://doi.org/10.21037/jtd.2018.03.182
doi: 10.21037/jtd.2018.03.182
pubmed: 30345104
pmcid: 6178301
Rice TW, Ishwaran H, Blackstone EH et al (2016) Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus 29:913–919. https://doi.org/10.1111/dote.12540
doi: 10.1111/dote.12540
pubmed: 27905171
Wang WP, He SL, Yang YS, Chen LQ (2018) Strategies of nodal staging of the TNM system for esophageal cancer. Ann Transl Med 6:77. https://doi.org/10.21037/atm.2017.12.17
doi: 10.21037/atm.2017.12.17
pubmed: 29666800
pmcid: 5890030
Yang Y, Huang X, Zhou L et al (2019) Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma. BMC Cancer 19:526. https://doi.org/10.1186/s12885-019-5755-5
doi: 10.1186/s12885-019-5755-5
pubmed: 31151431
pmcid: 6544972
Ishibashi Y, Tsujimoto H, Yaguchi Y, Kishi Y, Ueno H (2020) Prognostic significance of systemic inflammatory markers in esophageal cancer: systematic review and meta-analysis. Ann Gastroenterol Surg 4:56–63. https://doi.org/10.1002/ags3.12294
doi: 10.1002/ags3.12294
pubmed: 32021959
Liu JS, Huang Y, Yang X, Feng JF (2015) A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma. Am J Cancer Res 5:2180–2189
pubmed: 26328248
pmcid: 4548329
Wang P, Yang M, Wang X, Zhao Z, Li M, Yu J (2021) A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy. Ann Transl Med 9:233. https://doi.org/10.21037/atm-20-1460
doi: 10.21037/atm-20-1460
pubmed: 33708860
pmcid: 7940874
Panday VR, Huizing MT, Willemse PH et al (1997) Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 24:S1134–S1138
Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61:222–229. https://doi.org/10.1016/j.critrevonc.2006.09.006
doi: 10.1016/j.critrevonc.2006.09.006
pubmed: 17092739
Holditch SJ, Brown CN, Lombardi AM, Nguyen KN, Edelstein CL (2019) Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int J Mol Sci. https://doi.org/10.3390/ijms20123011
doi: 10.3390/ijms20123011
pubmed: 31226747
pmcid: 6627318
Gupta S, Portales-Castillo I, Daher A, Kitchlu A (2021) Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis 28:402–414. https://doi.org/10.1053/j.ackd.2021.08.001 . (e401)
doi: 10.1053/j.ackd.2021.08.001
pubmed: 35190107
Yuste AL, Aparicio J, Segura A et al (2003) Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2:231–234. https://doi.org/10.3816/CCC.2003.n.004
doi: 10.3816/CCC.2003.n.004
pubmed: 12620142
Buyukkor M, Tay F, Karacin C, Duran AO (2023) Prognostic markers after hepatic function impairment in patients with pancreatic adenocarcinoma. J Coll Physicians Surg Pak 33:32–36. https://doi.org/10.29271/jcpsp.2023.01.32
doi: 10.29271/jcpsp.2023.01.32
pubmed: 36597232
Saito T, Murakawa T, Shintani Y et al (2022) Japanese Joint Committee of Lung Cancer Registry. Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer. J Thorac Cardiovasc Surg 164:227-239.e6. https://doi.org/10.1016/j.jtcvs.2021.09.008
doi: 10.1016/j.jtcvs.2021.09.008
pubmed: 34600766
King PD, Perry MC (1995) Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin N Am 24:969–990
doi: 10.1016/S0889-8553(21)00236-3
Tsuzuki S, Kawano S, Fukuokaya W et al (2021) Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. Jpn J Clin Oncol 51:1665–1671. https://doi.org/10.1093/jjco/hyab115
doi: 10.1093/jjco/hyab115
pubmed: 34296282
Liu Y, Liu B, He Y et al (2021) Analysis of risk factors related to breast cancer metastasis: a retrospective nested case-control study. J BUON 26:1415–1421
pubmed: 34564999
Yuan Y, Yang F, Wang Y, Guo Y (2021) Factors associated with liver cancer prognosis after hepatectomy: a retrospective cohort study. Medicine (Baltimore) 100:e27378. https://doi.org/10.1097/MD.0000000000027378
doi: 10.1097/MD.0000000000027378
pubmed: 34678864
Huang H, Wang XP, Li XH et al (2017) Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma. BMC Cancer 17:544. https://doi.org/10.1186/s12885-017-3523-y
doi: 10.1186/s12885-017-3523-y
pubmed: 28806937
pmcid: 5556356
Wang M, Zou L, Liang J et al (2018) The urinary sarcosine/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer. Med Sci Monit 24:3034–3041. https://doi.org/10.12659/MSM.909949
doi: 10.12659/MSM.909949
pubmed: 29741162
pmcid: 5967288
Wang H, Shan D, Dong Y, Yang X, Zhang L, Yu Z (2021) Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer. Oncol Lett 21:73. https://doi.org/10.3892/ol.2020.12334
doi: 10.3892/ol.2020.12334
pubmed: 33365084
Waters JK, Reznik SI (2022) Update on management of squamous cell esophageal cancer. Curr Oncol Rep 24:375–385. https://doi.org/10.1007/s11912-021-01153-4
doi: 10.1007/s11912-021-01153-4
pubmed: 35142974
Cavallin F, Scarpa M, Cagol M et al (2018) Esophageal cancer clinical presentation: trends in the last 3 decades in a large Italian series. Ann Surg 267:99–104. https://doi.org/10.1097/SLA.0000000000002048
doi: 10.1097/SLA.0000000000002048
pubmed: 27759616
Liang H, Fan JH, Qiao YL (2017) Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med 14:33–41. https://doi.org/10.20892/j.issn.2095-3941.2016.0093
doi: 10.20892/j.issn.2095-3941.2016.0093
pubmed: 28443201
pmcid: 5365188
Li J, Zhu WL, Kang XX et al (2017) Prognostic factors and model of primary liver cancer treated with transcatheter arterial chemoembolization combined with radiofrequency ablation. Zhonghua Zhong Liu Za Zhi 39:787–791. https://doi.org/10.3760/cma.j.issn.0253-3766.2017.10.013
doi: 10.3760/cma.j.issn.0253-3766.2017.10.013
pubmed: 29061025
Kim JH, Seo SW, Chung CH (2018) What factors are associated with early mortality in patients undergoing femur surgery for metastatic lung cancer? Clin Orthop Relat Res 476:1815–1822. https://doi.org/10.1007/s11999.0000000000000101
doi: 10.1007/s11999.0000000000000101
pubmed: 30794217
pmcid: 6259786
Zhang P, Xi M, Li QQ et al (2014) The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer 5:689–695. https://doi.org/10.7150/jca.9569
doi: 10.7150/jca.9569
pubmed: 25258650
pmcid: 4174513
Liu Y, Chen J, Shao N, Feng Y, Wang Y, Zhang L (2014) Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma. World J Surg Oncol 12:43. https://doi.org/10.1186/1477-7819-12-43
doi: 10.1186/1477-7819-12-43
pubmed: 24568553
pmcid: 3938076
Maeda D, Sakane K, Kanzaki Y et al (2021) Relation of aspartate aminotransferase to alanine aminotransferase ratio to nutritional status and prognosis in patients with acute heart failure. Am J Cardiol 139:64–70. https://doi.org/10.1016/j.amjcard.2020.10.036
doi: 10.1016/j.amjcard.2020.10.036
pubmed: 33115639
Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, Bandinelli S, Antonelli Incalzi R, Picardi A (2018) Low alanine aminotransferase levels in the elderly population: frailty, disability, sarcopenia, and reduced survival. J Gerontol A Biol Sci Med Sci 73:925–930. https://doi.org/10.1093/gerona/glx126
doi: 10.1093/gerona/glx126
pubmed: 28633440
Pan YP, Hsu TY, Lin JY et al (2018) Prognostic significance of low body mass index and betel-quid use in the 5-year survival rates of esophageal squamous cell carcinoma patients. Nutr Cancer 70:1315–1321. https://doi.org/10.1080/01635581.2019.1588983
doi: 10.1080/01635581.2019.1588983
pubmed: 30900908
Chen SB, Liu DT, Chen YP (2022) Prognostic value of body mass index stratified by alcohol drinking status in patients with esophageal squamous cell carcinoma. Front Oncol 12:769824. https://doi.org/10.3389/fonc.2022.769824
doi: 10.3389/fonc.2022.769824
pubmed: 35251960
pmcid: 8891140
Yoon JP, Nam JS, Abidin M et al (2021) Comparison of preoperative nutritional indexes for outcomes after primary esophageal surgery for esophageal squamous cell carcinoma. Nutrients. https://doi.org/10.3390/nu13114086
doi: 10.3390/nu13114086
pubmed: 34836432
pmcid: 8618700
Preuss HG, Kaats GR, Mrvichin N, Bagchi D, Preuss JM (2019) Circulating ALT levels in healthy volunteers over life-span: assessing aging paradox and nutritional implications. J Am Coll Nutr 38:661–669. https://doi.org/10.1080/07315724.2019.1580169
doi: 10.1080/07315724.2019.1580169
pubmed: 31075051
Srivastava AR, Kumar S, Agarwal GG, Ranjan P (2007) Blunt abdominal injury: serum ALT-A marker of liver injury and a guide to assessment of its severity. Injury 38:1069–1074. https://doi.org/10.1016/j.injury.2007.04.019
doi: 10.1016/j.injury.2007.04.019
pubmed: 17686485
Chen L, Qian J, Lin L et al (2021) Prognostic value of preoperative lymphocyte-to-monocyte ratio in oral cancer patients and establishment of a dynamic nomogram. Oral Dis 27:1127–1136. https://doi.org/10.1111/odi.13629
doi: 10.1111/odi.13629
pubmed: 32881142
Zheng RR, Huang XW, Liu WY et al (2017) Nomogram predicting overall survival in operable cervical cancer patients. Int J Gynecol Cancer 27:987–993. https://doi.org/10.1097/IGC.0000000000000987
doi: 10.1097/IGC.0000000000000987
pubmed: 28498238
He Y, Mao M, Shi W et al (2019) Development and validation of a prognostic nomogram in gastric cancer with hepatitis B virus infection. J Transl Med 7:98. https://doi.org/10.1186/s12967-019-1841-3
doi: 10.1186/s12967-019-1841-3
Delanaye P, Cavalier E, Pottel H (2017) Serum creatinine: not so simple! Nephron 136:302–308. https://doi.org/10.1159/000469669
doi: 10.1159/000469669
pubmed: 28441651
Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953
doi: 10.1093/clinchem/38.10.1933
pubmed: 1394976
Yang M, Zhang Q, Ruan GT et al (2021) Association between serum creatinine concentrations and overall survival in patients with colorectal cancer: a multi-center cohort study. Front Oncol 11:710423. https://doi.org/10.3389/fonc.2021.710423
doi: 10.3389/fonc.2021.710423
pubmed: 34692487
pmcid: 8529284
Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, Albanes D (2009) Serum creatinine and prostate cancer risk in a prospective study. Cancer Epidemiol Biomark Prev 18:2643–2649. https://doi.org/10.1158/1055-9965.EPI-09-0322
doi: 10.1158/1055-9965.EPI-09-0322
das Neves W, Alves CRR, de Souza Borges AP, de Castro G Jr (2021) Serum creatinine as a potential biomarker of skeletal muscle atrophy in non-small cell lung cancer patients. Front Physiol 12:625417. https://doi.org/10.3389/fphys.2021.625417
doi: 10.3389/fphys.2021.625417
pubmed: 33912068
pmcid: 8072336
Zyczkowski M, Prokopowicz G, Taborowski P et al (2018) Basic parameters of blood count, serum sodium, and creatinine as prognostic factors for renal cell carcinoma at five-year follow-up. Med Sci Monit 24:3895–3902. https://doi.org/10.12659/MSM.906867
doi: 10.12659/MSM.906867
pubmed: 29885161
pmcid: 6024718
Cai G, Yu J, Meng X (2020) Predicting prognosis and adverse events by hematologic markers in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Cancer Manag Res 12:8497–8507. https://doi.org/10.2147/CMAR.S257058
doi: 10.2147/CMAR.S257058
pubmed: 33061564
pmcid: 7519412
Ding T, Liu C, Huang B et al (2021) A survival prediction nomogram for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy followed by surgery. Cancer Manag Res 13:7771–7782. https://doi.org/10.2147/CMAR.S329687
doi: 10.2147/CMAR.S329687
pubmed: 34675672
pmcid: 8519412